Author: kfragioudaki

  • All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

Presentation to the Hellenic Fund and Asset Management Association Paiania, 24 April 2024 – Lavipharm held today its Annual Analysts Briefing, in accordance with the Company’s financial calendar for 2024. The presentation took place at the Athens Exchange to the members of the Hellenic Fund...

Flash Note Ετήσια Οικονομικά Αποτελέσματα 2023 (Μη ελεγμένα χρηματοοικονομικά στοιχεία) Παιανία, 28 Φεβρουαρίου 2024 - Η Lavipharm A.E.  ενημερώνει το επενδυτικό κοινό για τα βασικά οικονομικά μεγέθη για τη χρήση  2023, καθώς και τις εξελίξεις στη δραστηριότητά της: Οι ενοποιημένες Πωλήσεις από συνεχιζόμενη δραστηριότητα  προ Rebate & Clawback...

Paiania, 16 February 2024 - “Lavipharm S.A, pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces the Financial Calendar of 2024, as follows :   Wednesday, 28 February 2024 Flash Note Financial Results of the FY.2023 Thursday, 21 March 2024 Announcement of the FY.2023 Financial Report Wednesday, 24...

Peania, 14 February 2024 - Lavipharm S.A., in accordance with Regulation (EU) 596/2014, announces the cessation of the Group’s pharmaceutical wholesale activities and logistics services to third parties (3PL), and the transfer of certain assets of its subsidiary LAS to Profarm S.A. Special attention has...

Paiania, 11 December 2023 – Lavipharm S.A. announced today, in accordance with Regulation 596/2014/EU, that it has entered into an Asset Purhase Agreement with Sanofi for the acquisition of the pharmaceutical product Flagyl® for the Greek market. Commercialization of the product by Lavipharm is expected to...

Paiania, 11 December 2023 – Lavipharm S.A. announced today, in accordance with Regulation 596/2014/EU, that it has entered into an Asset Purhase Agreement with Sanofi for the acquisition of the pharmaceutical product Flagyl® for the Greek market. Commercialization of the product by Lavipharm is expected to...

Paiania, 6 December 2023 - Marking a remarkable year since its successful Share Capital Increase, Lavipharm, the sole Greek pharmaceutical company listed on the Athens Stock Exchange, proudly commenced today’s trading session. At this special event held at the Athens Exchange, Telemaque Lavidas, Executive Board...